RECORDED: November 15, 2022, 9:00 am – 10:00 am EST
Long-Acting Injectable Cabotegravir for HIV Prevention: Promises and Pitfalls
As regulatory approvals for long-acting, injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) against HIV move forward, Raphael J. Landovitz, MD, MSc, HPTN 03 Protocol Chair, discusses findings from the randomized controlled trial and ongoing open-label extension phases of the studies, including some thoughts on opportunities and challenges of clinical implementation in this grand rounds.
Introductory Remarks
Jessica Justman, MD, Senior Technical Director, ICAP at Columbia University.
Presentation
Raphael J. Landovitz, MD, MSc, Professor of Medicine, Division of Infectious Diseases, David Geffen School of Medicine, University of California, Los Angeles
